Phase 3 AEGEAN trial results show the benefit of perioperative immunotherapy-based treatment for NSCLC. Nierengarten MB. Cancer 2024;130:495-496.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Nierengarten MB. Phase 3 AEGEAN trial results show the benefit of perioperative immunotherapy-based treatment for NSCLC. Cancer 2024;130:495-496.
PMID: 38329434